I promise

"I promise, Suzy... Even if it takes the rest of my life." - Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is Triple Negative Breast Cancer?

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" type of cancer. Being Triple Negative, you don't have a targeted therapy and that your only treatment option is chemotherapy.

Triple Negative is seen in about 15% of all breast cancers. Triple Negative is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TN is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Wednesday, August 14, 2019

Toledo Jeep Fest Parade 2019


August 2019, over 1200 jeeps rolled through downtown Toledo, Ohio for their annual Jeep Fest Weekend.

Me watching Jeep Parade

Love my Muddy Mud hen!

Miracles are Pink

Winged Warrior

Pink!

Thursday, August 1, 2019

Young Researchers in Triple Negative Breast Cancer 2019

It's always an honor to go to University of Toledo's Pharmaceutical Science research lab and see first hand what they are working on and the progression of their studies. On July 3, 2019, Dr. Angelique treated me lunch on campus the day before she was about to leave UT for Boston where she will continue her career in pharmaceutical research and wishes to continue her research in Triple Negative Breast Cancer.  Saloni of UT will continue researching drug resistance in Triple Negative Breast Cancer in Dr. Amit Tiwari's lab.

Melissa and Dr. Angelique 
in her research office

Triple Negative Breast Cancer cells
under the microscope

Saloni viewing results of her study on
Triple Negative Breast Cancer cells

Untreated Triple Negative Breast Cancer Cells

Triple Negative Breast Cancer cells
after being treated with an experimental drug,

destroying the cancer cells.  

Sunday, June 23, 2019

YSC Conference Orlando 2018




Warm weather, palm trees,
and cool cars!

Celebrating 20 years of young survival coalition

YSC CEO, Jennifer Merschdorf

 #SquirrelPack4Life YSC reunion

Melissa and Dusty

Tammy, Melissa and Dusty

Until we see you again, Dusty

Tammie and TNBC sisters, Angie Martin, Melissa,
Alex and Jeanna

TNBC sisters Melissa and Karen Koon

Breast Cancer survivors
Tammie and Melissa
#KissThis4MBC

Breast Cancer can
#KissThis4MBC!

#KissThis4MBC campaign

Kick Ass Survivor Melissa
advertising for Healing Heels
https://www.healing-heels.com

Kick Ass (in heels)

A Story Half Told
Remembering Jill Cohen

https://www.storyhalftold.com/meet-jill-cohen

TNBC sisters Melissa, Jeanna, Sara and Lisa
advertising for Triple Negative Breast Cancer
Foundation and promoting
#TNBCDay
https://www.tnbcfoundation.org

TNBC sisters with Roxanne on right

TNBC sisters Melissa and Laura D'Alessandro

TNBC sisters Melissa and Joanne Hayashi
"3 negative"

TNBC sisters Melissa and
Alison Mcquillan

TNBC sisters forever!
Angela Martin and Melissa

TNBC Sisters Angie, Melissa
and Laura

TNBC sisters Melissa and
Laura Shepard

Breast Cancer survivors
Melissa and Carol Capelan

Love this group of YSC survivor sisters!

Lookie here:
 HOPE in Triple Negative Breast Cancer

Immunomedics pipeline,
Hope in Triple Negative Breast Cancer

Preliminary data shows clinical benefit in patients
with mTNBC with Sacituzumab goviitecan
targeting Trop-2, an epithelial antigen expressed
on many solid tumors

ASCENT Phase 3 study recruiting
Metastatic TNBC patients
http://tnbctrial.com

Metastatic Triple Negative Breast Cancer Background:
- 15% of all breast cancer cases
- Aggressive with poor prognosis
- Short response with rapid relapse, 
  visceral and brain mets are common
- Progression-free survival of 1.7 to 3.7 months
- Median overall survival of 10 to 13 months 

2017  Current studies of Standard of care
treatments for mTNBC:

- Carboplatin
- Docetaxel
- Cisplatin/carboplatin
- Ixabepilone
- Capecitabine
- Eribulin

Breast cancer sisters, Terlisa Sheppard 
and Melissa

I love the 90's theme
TNBC sisters Melissa and Jeanna Holler

Breast cancer sisters Melissa 
and Susan Portnoy

CEO of Young Survival Coalition,
Jennifer Merschdorf and Melissa

20 years of Young Survival Coalition!
Breast cancer sisters Melissa and Kelsey

In memory of YSC sisters
Lisa Barmettler and
Juls Raschal

Breast cancer sisters Jocelyn Banks
from the SCAR Project and
http://www.mommyhasbreastcancer.org
and Melissa

Breast cancer sisters Shay Sharpe, 
Melissa and Nikki Tripplett

TNBC sisters Melissa Richardson
and Melissa Paskvan

Breast cancer sisters Miri Mogilevsky
and Melissa

Speaker Julie Larson on what's NORMAL
in surviving breast cancer

Speaker Julie Larson on "And at the same time..."

Unconditionally love Life!

My forever #SquirrelPack4Life
Dusty, Melissa, Mary Peters, Jeanna, Angie Martin,
Alexandra , Sara, Lisa and Tammie

Total Pageviews

Click to help fund mammograms for the uninsured

The Breast Cancer Site

"click image to link"